Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The VERDICT trial found that ulcerative colitis patients treated with vedolizumab who achieved full disease clearance had a longer time to their first UC-related complication compared to those who only reached symptomatic remission. Nearly 60% of patients hit their corticosteroid-free target by 48 weeks. It's the first randomized evidence supporting treat-to-target strategies in UC.
The VERDICT trial has delivered the first randomized evidence that aiming for full disease clearance — not just symptom relief — in ulcerative colitis (UC) patients actually delays complications. Presented at United European Gastroenterology Week in Barcelona, the study evaluated intravenous vedolizumab (Entyvio, Takeda) and found that patients who achieved corticosteroid-free disease clearance by 16 weeks fared better long-term than those who only reached corticosteroid-free symptomatic remission.
This is a meaningful step forward because it's the first prospective, randomized study to test whether hitting deeper treatment targets translates into real clinical benefit for UC patients — and the answer appears to be yes.
By the Numbers:
Why it matters: These findings give clinicians the first hard randomized data to back treat-to-target guidelines in UC, potentially reshaping how aggressively gastroenterologists pursue disease clearance over simple symptom control.
